Abera Bioscience ABNGM: ABERA

ABERA: Transition to clinical-stage vaccines, strong financing, and expanded R&D drive future growth

· Issued by Abera Bioscience AB

Strong progress in vaccine development with transition to clinical phase, robust financing from grants and share issues, and a widened pipeline. Net loss increased due to higher R&D costs, but cash position and equity improved significantly.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Abera Bioscience AB on 6ix

Earlier from Abera Bioscience

Later from Abera Bioscience

All Abera Bioscience news releases